ABL Texcell Diagnostics publishes a proof of concept combining five tests in a single sequencing run
ABL Texcell Diagnostics announced the publication, on 3 November 2026 in the journal Antibiotics, of a study by its researchers combining five targeted sequencing applications in a single run on MGI's DNBSEQ-E25 platform. The authors describe it as a technical proof of concept.
Five applications, 25 libraries and 82.6% on-target reads
The study, authored by Drali R. et al., concerned the pooling of DeepChek libraries from five infectious disease applications in a single sequencing run, followed by a pathogen-specific bioinformatic analysis using the MicrobioChek software.
In total, 25 libraries prepared from 21 distinct materials produced 39,962,528 read pairs, of which 82.6% were on target. For tuberculosis, the two reference materials gave resistance interpretations consistent with the expected classifications, and the 13 target amplicons reached complete coverage at at least 100×.
The 11 HIV-1 pol region libraries achieved 100% coverage at at least 100×, compared with 89.4% to 91.1% for the two whole-genome libraries.
The six influenza libraries covered 100% of the eight viral segments, which enabled subtype and HA clade assignment, with support from the Nextclade tool.
For cytomegalovirus, six genes were covered in simplex format, but multiplex coverage was complete for only five of them, which, according to the study, highlights the need to assess depth gene by gene.
For bacterial identification by full-length 16S, two reference libraries yielded sequences consistent with the expected organisms, with acknowledged limitations at the species level.
A single run, without replication or established cost gains
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The authors argue that combining complementary tests in a single run could help laboratories coordinate instrument use and streamline downstream analysis. They nevertheless specify that the benefits in time, cost and routine clinical performance remain to be established through broader, replicated evaluations.
The accompanying scientific note points out that the trial relies on a single run, without replication, and that it establishes neither analytical reproducibility, nor clinical sensitivity or specificity, nor time or cost gains. The regulatory status and research use depend on each product reference and each territory.
The company, based in Woippy, invites interested laboratories to contact it regarding its DeepChek tests, its DNBSEQ-compatible library preparation (references 203A and 204A), and its MicrobioChek analysis tool.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 13,8 millions d'euros
Management commentary: Sur la base des informations commerciales, opérationnelles et comptables disponibles à la date du présent communiqué, la Société anticipe désormais un chiffre d'affaires compris entre 13,5 M€ et 14,0 M€. Cette fourchette actualise l'objectif de 12,265 M€ publié le 1er juin 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.